Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL

Experts discuss the use of chimeric antigen receptor T-cell (CAR T) therapies, specifically axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), in the second-line setting for patients with diffuse large B-cell lymphoma (DLBCL), focusing on patient selection and treatment frequency.

Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.

Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and tisagenlecleucel [tisa-cel]).

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process.

Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.

Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.

Experts discuss recent data updates from the TRANSCEND CLL-004 study on the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib, the potential curative role of chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and the future outlook for CAR T in treating R/R CLL.

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

Experts share their closing thoughts and key take-home messages from this discussion.